X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9034) 9034
Publication (1038) 1038
Book Chapter (87) 87
Book Review (71) 71
Dissertation (59) 59
Conference Proceeding (39) 39
Government Document (31) 31
Magazine Article (7) 7
Book / eBook (1) 1
Data Set (1) 1
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5949) 5949
her2 (5866) 5866
index medicus (4948) 4948
female (4641) 4641
oncology (4369) 4369
breast cancer (4215) 4215
trastuzumab (2821) 2821
receptor, erbb-2 - metabolism (2383) 2383
cancer (2345) 2345
middle aged (2196) 2196
breast neoplasms - pathology (2063) 2063
aged (1825) 1825
adult (1769) 1769
immunohistochemistry (1741) 1741
breast neoplasms - drug therapy (1693) 1693
receptor, erbb-2 - genetics (1633) 1633
breast neoplasms - metabolism (1611) 1611
chemotherapy (1561) 1561
expression (1491) 1491
prognosis (1407) 1407
animals (1323) 1323
breast neoplasms - genetics (1304) 1304
therapy (1289) 1289
cell line, tumor (1207) 1207
skin and connective tissue diseases (1196) 1196
breast-cancer (1069) 1069
epidermal growth factor (1057) 1057
tumors (1049) 1049
pathology (1039) 1039
metastasis (1034) 1034
gene amplification (1031) 1031
mice (942) 942
analysis (940) 940
survival (933) 933
medicine & public health (910) 910
research (905) 905
care and treatment (898) 898
male (881) 881
aged, 80 and over (876) 876
antineoplastic agents - therapeutic use (864) 864
monoclonal-antibody (838) 838
her2/neu (818) 818
carcinoma (814) 814
cell biology (749) 749
growth-factor receptor (721) 721
in-situ hybridization (716) 716
treatment outcome (716) 716
egfr (707) 707
amplification (706) 706
antibodies, monoclonal, humanized (667) 667
erbb-2 protein (658) 658
receptor (654) 654
biochemistry & molecular biology (635) 635
genetic aspects (633) 633
neoplasms (625) 625
article (623) 623
receptor, erbb-2 - analysis (622) 622
antineoplastic combined chemotherapy protocols - therapeutic use (620) 620
proteins (619) 619
receptor, erbb-2 - antagonists & inhibitors (618) 618
gene expression (614) 614
adjuvant chemotherapy (609) 609
overexpression (605) 605
neoplasm staging (590) 590
in situ hybridization, fluorescence (573) 573
lapatinib (565) 565
gene expression regulation, neoplastic (556) 556
retrospective studies (554) 554
health aspects (553) 553
biomarkers, tumor - metabolism (529) 529
pharmacology & pharmacy (511) 511
antineoplastic agents - pharmacology (510) 510
cells (508) 508
cancer therapies (490) 490
disease-free survival (488) 488
resistance (485) 485
growth (484) 484
receptor, erbb-2 - biosynthesis (484) 484
breast neoplasms - mortality (480) 480
estrogen-receptor (479) 479
cancer research (474) 474
her-2/neu (471) 471
gastric cancer (464) 464
receptor, erbb-2 - immunology (456) 456
erbb2 (444) 444
signal transduction (444) 444
kinases (432) 432
antibodies, monoclonal - therapeutic use (431) 431
biomarkers, tumor - analysis (427) 427
breast neoplasms - diagnosis (425) 425
medicine, research & experimental (425) 425
apoptosis (407) 407
mutation (402) 402
medical prognosis (401) 401
development and progression (399) 399
estrogen (397) 397
receptors, estrogen - metabolism (396) 396
surgery (395) 395
phase-ii (391) 391
activation (388) 388
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8927) 8927
French (95) 95
Japanese (77) 77
German (54) 54
Chinese (30) 30
Polish (20) 20
Spanish (18) 18
Korean (16) 16
Russian (7) 7
Hungarian (3) 3
Persian (3) 3
Swedish (3) 3
Czech (2) 2
Portuguese (2) 2
Turkish (2) 2
Bosnian (1) 1
Catalan (1) 1
Norwegian (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 07/2016, Volume 107, Issue 7, pp. 1039 - 1046
Antibody–drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic... 
topoisomerase I inhibitor | T‐DM | HER2 | bystander killing | Antibody‐drug conjugate | T-DM | Antibody-drug conjugate | HODGKINS LYMPHOMA | GEMTUZUMAB OZOGAMICIN | ADVANCED BREAST-CANCER | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | TRASTUZUMAB EMTANSINE | CHALLENGES | THERAPY | ONCOLOGY | EXPRESSION | CATHEPSIN-B | Receptor, ErbB-2 - genetics | Breast Neoplasms - immunology | Humans | Stomach Neoplasms - pathology | Maytansine - pharmacology | Immunoconjugates - immunology | Breast Neoplasms - enzymology | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Neoplasms - genetics | Antibodies, Monoclonal, Humanized - pharmacology | Female | Camptothecin - immunology | Receptor, ErbB-2 - immunology | Camptothecin - analogs & derivatives | Stomach Neoplasms - enzymology | Stomach Neoplasms - genetics | Maytansine - analogs & derivatives | Neoplasms - enzymology | Stomach Neoplasms - immunology | Animals | Breast Neoplasms - genetics | Bystander Effect - drug effects | Breast Neoplasms - pathology | Mice, Nude | Neoplasms - immunology | Cell Membrane Permeability - drug effects | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C | Antibodies, Monoclonal, Humanized - immunology | Neoplasms - pathology | Camptothecin - pharmacology | Maytansine - immunology | Trastuzumab | Viral antibodies | Epidermal growth factor | Imaging systems | Antibodies | Permeability | Drug therapy | Biopharmaceutics | Tumors | Antigens | Hematology | Laboratories | Toxicity | DNA topoisomerase | Polymerization | Clinical trials | Cytotoxicity | Breast cancer | ErbB-2 protein | Stomach cancer | Hypotheses | Antitumor agents | Xenografts | Antitumor activity | Lymphomas | Drug dosages | Payloads | Index Medicus | Original
Journal Article
Journal Article
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 02/2014, Volume 138, Issue 2, pp. 241 - 256
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2018, Volume 103, pp. 52 - 60
Although targeting human epidermal growth factor receptor 2 (HER2) is a meaningful treatment in HER2-positive breast cancer, ultimately resistance develops.... 
Immune cell infiltration | Trastuzumab resistance | Androgen receptor expression | HER2-positive metastatic breast cancer | SURVIVAL | BENEFIT | TRASTUZUMAB | PROSTATE-CANCER | ANTIBODY | HER2 | CHEMOTHERAPY | PLUS | ONCOLOGY | Immunohistochemistry | Epidermal growth factor | Cell death | Analysis | Estrogen | Breast cancer | Metastasis | T cells | Macrophages
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5529 - 5537
Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth... 
AROMATASE INHIBITOR | OVEREXPRESSION | ONCOLOGY | SERUM HER-2/NEU | TAMOXIFEN | RESISTANCE | LETROZOLE | ENDOCRINE THERAPY | COMBINATION | HER2 | ESTROGEN-RECEPTOR | Receptors, Estrogen - blood | Triazoles - administration & dosage | Triazoles - adverse effects | Confidence Intervals | Postmenopause - drug effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Adenocarcinoma - metabolism | Statistics, Nonparametric | Aged, 80 and over | Female | Drug Administration Schedule | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Adenocarcinoma - secondary | Biomarkers, Tumor - blood | Disease-Free Survival | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Nitriles - adverse effects | Receptors, Progesterone - blood | Receptor, ErbB-2 - blood | Trastuzumab | Adenocarcinoma - mortality | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 5, pp. 443 - 451
Journal Article